Powder: -20°C for 3 years
In solvent: -80°C for 2 years
MAGL-IN-4 is one of the monoacylglycerol Lipase (MAGL) inhibitors in central nervous system-related diseases.
Description | MAGL-IN-4 is one of the monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases. |
Targets&IC50 | MAGL:6.2 nM |
In vitro | MAGL-IN-4 showed potent in vitro MAGL inhibitory activity (IC50 6.2 nM), good oral absorption and blood-brain barrier penetration[1]. |
In vivo | MAGL-IN-4 showed significant pharmacodynamic changes (2-arachidonoylglycerol increase and arachidonic acid decrease) at 0.3-10 mg/kg, po. in mice[1]. |
Synonyms | His121 ARG57 |
Molecular Weight | 364.82 |
Formula | C18H21ClN2O4 |
CAS No. | 2135785-20-3 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 88 mg/mL (241.21 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MAGL-IN-4 2135785-20-3 Metabolism Lipase Monoacylglycerol lipase CB1 lipase monoacylglycerol CB2 Inhibitor inhibit BBB barrier MAGLIN4 MAGL IN 4 blood-brain endocannabinoid His121 ARG57 hERG FAAH 2-AG ABHD6 MAGL inhibitor